Clinical genitourinary cancer最新文献

{"title":"Eighty-Nine Cases of Primary Prostatic Signet Ring Cell Carcinoma-Systematic Review.","authors":"Madison Boot, Kenneth Keen Yip Chew, Jack Archer, Kirra Parks, Katelyn Wilson, Cameron Sowter, Steven Sowter","doi":"10.1016/j.clgc.2024.102281","DOIUrl":"10.1016/j.clgc.2024.102281","url":null,"abstract":"<p><p>Signet ring cell adenocarcinoma is a rare subtype of mucinous adenocarcinoma that affects the gastrointestinal tract and the prostate. Prostatic signet ring cell carcinoma comprises 0.02% of all cases of prostate cancer and 0.4% of all signet ring cell cancers. The aim of this review was to summarize the existing literature on primary prostatic signet ring cell carcinoma by assessing patient demographics, clinical presentations, investigations, treatment methods, and survival outcomes. A systematic review was conducted in multiple databases, including 46 articles comprising 89 individual cases of primary prostatic signet ring cell carcinoma. Data was extracted and analyzed using descriptive statistics. The average age of patients with primary prostatic signet ring cell carcinoma was 68.5 years, and most cases were reported in Caucasian individuals. Clinical presentations varied, with lower urinary tract symptoms being the most common. Biochemical markers, such as prostate-specific antigen, were often elevated. Imaging modalities, including computed tomography and magnetic resonance imaging, were used for diagnosis, and it found that one-third had metastatic disease on diagnosis. Treatment options included radical prostatectomy, hormone therapy, radiation therapy, and chemotherapy. The prognosis for primary prostatic signet ring cell carcinoma was poor, with a 3-year survival rate of approximately 17%. Primary prostatic signet ring cell carcinoma is a rare and aggressive form of prostate cancer. The limited literature on this condition highlights the need for further research. These systematic review findings contribute to a better understanding of this disease and may guide future clinical management strategies.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"23 1","pages":"102281"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Comprehensive Treatment Outcomes and Prognostic Insights From a Multicenter Real-World Study (YUSHIMA Study).","authors":"Yuki Nakamura, Hajime Tanaka, Noboru Numao, Masaharu Inoue, Atsushi Yoshinaga, Naoko Kawamura, Kenji Tanabe, Keita Izumi, Takanobu Yamamoto, Sho Uehara, Yuya Maezawa, Takahiko Soma, Masahiro Toide, Ryoji Takazawa, Saori Araki, Soichiro Yoshida, Yasuhisa Fujii","doi":"10.1016/j.clgc.2025.102301","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102301","url":null,"abstract":"<p><strong>Introduction: </strong>Enfortumab vedotin (EV) currently plays a predominant role in the evolving treatment paradigm of metastatic urothelial carcinoma (mUC). However, large-scale real-world data on EV remain limited. This multicenter retrospective study comprehensively evaluated treatment outcomes and prognostic factors of EV monotherapy for mUC.</p><p><strong>Patients and methods: </strong>A total of 115 consecutive patients with mUC who received EV monotherapy between 2021 and 2023 were analyzed. Baseline characteristics and treatment outcomes were collected. Progression-free survival (PFS), over-all survival (OS), best overall response, treatment-related adverse events (TRAEs), and prognostic factors associated with PFS and OS were analyzed.</p><p><strong>Results: </strong>The median age was 74 years, and 18 patients (16%) had an performance status (PS) of ≥2. During the median follow-up of 7.1 months, median PFS was 6.7 months and median OS was 12.9 months. Eighty-six patients (74%) experienced interruption or dose reduction of EV, resulting in a median relative dose intensity (RDI) of 77.4%. The objective response rate was 49%, and the disease control rate was 69%. Eighty-eight patients (77%) experienced TRAEs, including cutaneous AEs observed in 58 patients (50%). In multivariable analysis using pretreatment factors, PS≥1, liver metastasis, and low albumin level were associated with shorter PFS and OS. With RDI and AEs incorporated in the models, the presence of cutaneous AE was independently associated with longer PFS and OS.</p><p><strong>Conclusion: </strong>This real-world study demonstrated comparable treatment efficacy and acceptable TRAEs compared to clinical trials. The presence of cutaneous AE is a potentially favorable prognostic factor for mUC patients treated with EV.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102301"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinically Meaningful Upstaging and Upgrading in Favorable Intermediate-Risk Radical Prostatectomy Patients.","authors":"Mattia Longoni, Francesco Di Bello, Natali Rodriguez Peñaranda, Fabian Falkenbach, Andrea Marmiroli, Quynh Chi Le, Zhe Tian, Jordan A Goyal, Nicola Longo, Stefano Puliatti, Markus Graefen, Ottavio de Cobelli, Felix K H Chun, Fred Saad, Shahrokh F Shariat, Giorgio Gandaglia, Francesco Montorsi, Alberto Briganti, Pierre I Karakiewicz","doi":"10.1016/j.clgc.2025.102300","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102300","url":null,"abstract":"<p><strong>Introduction: </strong>In NCCN favorable intermediate-risk (FIR) prostate cancer (PCa) patients treated with radical prostatectomy (RP), we tested the effect of upstaging and upgrading on cancer-specific mortality (CSM).</p><p><strong>Methods: </strong>Within the SEER database (2010-2021), upstaging (≥pT3a or pN1) and upgrading (ISUP ≥3) rates in FIR RP patients were tabulated. Kaplan-Meier (KM) plots and multivariable Cox-regression models (CRMs) were fitted.</p><p><strong>Results: </strong>In 9,037 FIR RP PCa patients, 1,136 (12.6%) exhibited upstaging, 1,341 (14.8%) upgrading, and 377 (4.2%) both vs. 6,937 (76.8%) that did not. Of all upstaged patients, 812 (71.5%) harbored pT3a vs. 324 (28.5%) ≥pT3b/pN1 stage. Of all upgraded patients, 1,077 (80.3%) harbored ISUP 3 vs. 264 (19.7%) ISUP ≥4. Of all upstaged and upgraded patients, 46 (12.2%) exhibited both ≥pT3b/pN1 and ISUP ≥4. Ten-year CSM-free rates in upstaged (96.0%), upgraded (95.9%) and combined upstaged and upgraded (91.0%) patients were significantly lower (P < .001) than others (98.9%). Significantly lower 10-year CSM-free rates were recorded in ≥pT3b/pN1-only (91.9%), ISUP ≥4-only (94.6%), and combined ≥pT3b/pN1 and ISUP ≥4 (85.3%) patients (all P < .05). In multivariable CRMs, upstaging (HR: 3.8), upgrading (HR: 3.5) as well as both upstaging and upgrading (HR: 8.3), independently increased CSM. Specific upstaging to ≥pT3b/pN1-only, upgrading to ISUP ≥4-only, and both upgrading and upstaging independently increased CSM by 3.5-, 6.7-, and 26-fold, respectively.</p><p><strong>Conclusion: </strong>Of all FIR RP patients, the vast majority is neither upstaged nor upgraded. Those with ≥pT3b/pN1 upstaging, ISUP ≥4 upgrading, or both are at high, higher, and extremely elevated risk of CSM, respectively, and thus require special considerations.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102300"},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Renal Lymphoma: A Single-Center Study of 14 Cases.","authors":"Tao Wang, Yunxia An, Hongyun Zhai, Houming Zhao, Xiaohui Ding","doi":"10.1016/j.clgc.2025.102299","DOIUrl":"https://doi.org/10.1016/j.clgc.2025.102299","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics, pathology, imaging features, and prognosis of primary renal lymphoma (PRL), a rare malignancy.</p><p><strong>Patients and method: </strong>We conducted a retrospective review of 14 PRL cases diagnosed between January 2009 and January 2022, with follow-up data collected from medical records.</p><p><strong>Results: </strong>The study included 14 patients (7 males, 7 females), with a mean age of 60.4 years. All cases were unilateral, with 6 involving the left kidney and 8 the right. Eleven patients underwent radical nephrectomy, and two had partial nephrectomy. Pathological subtypes included 8 cases of diffuse large B-cell lymphoma (DLBCL), 5 of extranodal marginal zone B-cell lymphoma (MZBL), and 1 of extranodal NK/T-cell lymphoma. Nine patients received 4-6 cycles of adjuvant chemotherapy: 4 with the R-CHOP regimen, 4 with CHOP, and 1 with COP-L combined with chidamide for extranodal NK/T-cell lymphoma. By June 2022, 7 patients were alive, while 7 had died, 5 of whom did not receive adjuvant chemotherapy. The median progression-free survival (PFS) was 33 months, and the median overall survival (OS) was 38 months.</p><p><strong>Conclusions: </strong>PRL is a rare lymphoma, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. Nephrectomy followed by R-CHOP chemotherapy is recommended as the treatment approach, and early diagnosis is essential for improving patient outcomes.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":" ","pages":"102299"},"PeriodicalIF":0.0,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Bladder Outlet Obstruction Releated to Recurrence In Low Risk Ta Low Grade Non Muscle Invasive Bladder Cancer?","authors":"Serhat Yentur, Yunus Emre Dusunus, Ismail Ulus, Ismail Engin Kandirali, Sergen Sahin","doi":"10.1016/j.clgc.2024.102296","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.102296","url":null,"abstract":"<p><strong>Introduction: </strong>Bladder cancer is common in men. The number of recurrences is one of the risk factors for progression and poor prognosis in nonmuscle invasive bladder cancer (NMIBC). We aimed to investigate whether bladder outlet obstruction (BOO) has an effect on bladder cancer recurrence in patients with nonmuscle invasive bladder cancer.</p><p><strong>Materials and methods: </strong>Data from 207 male patients with nonmuscle invasive bladder cancer (NMIBC) diagnosed between November 2008 and March 2023, with low risk Ta Low-Grade tumors were retrospectively reviewed. Patients were divided into 2 groups as bladder outlet obstruction (n:133) and nonobstruction (n:74). We analyzed the results of the effect of obstruction on bladder cancer recurrence.</p><p><strong>Results: </strong>Recurrence rates of patients with bladder outlet obstruction were found to be higher in Kaplan-Meier analysis. The log-rank test result of P = .034 was statistically significant at 5% significance level. Cox regression analysis revealed that bladder outlet obstruction had an increasing effect on recurrence (P = .049), while other variables (smoking, age, postmicturition residual [PMR]) did not create a significant difference in the risk of recurrence.</p><p><strong>Conclusion: </strong>The presence of bladder outlet obstruction is a factor that increases the risk of recurrence. In bladder cancer patients, early treatment of bladder outlet obstruction will not only reduce the tumor recurrence rate but also have a positive impact on the patient's quality of life.</p>","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"23 2","pages":"102296"},"PeriodicalIF":0.0,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of a multidisciplinary tumour board (MTB) on treatment decision making for patients with renal cell carcinoma (RCC): 5-year data analysis","authors":"L. Brink, A. Ruiter, B. Lagerveld, N. Graafland, A. Bex, H. Beerlage, R.J.M. van Moorselaar, P. Zondervan","doi":"10.1016/j.clgc.2024.01.021","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.01.021","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"327 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139822790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Radical Cystectomy in Clinically Node Positive Bladder Cancer: A US Veterans Health Administration Study","authors":"Margaret Meagher, Kylie M. Morgan, Leah N. Deshler, Dhruv Puri, Kit Yuen, Aditya Bagrodia, Brent Rose, Tyler F Stewart, A. Salmasi","doi":"10.1016/j.clgc.2024.02.006","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.02.006","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"76 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139887499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns and survival outcomes before and after access to immune checkpoint inhibitors for patients with metastatic urothelial carcinoma: A single-centre retrospective study from 2004 to 2021.","authors":"Jose C. Tapia, Freya Bosma, J. Gavira, Sofia Sanchez, Maria Alejandra Molina, J. Sanz-Beltran, Cristina Martín-Lorente, G. Anguera, Pablo Maroto","doi":"10.1016/j.clgc.2024.01.019","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.01.019","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139815806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of Cystatin C-Based Sarcopenia Index in Patients Undergoing Surgery for Renal Tumors","authors":"S. Yajima, Y. Nakanishi, Ryo Andy Ogasawara, Naoki Imasato, Kohei Hirose, Sao Katsumura, M. Kataoka, H. Masuda","doi":"10.1016/j.clgc.2024.02.002","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.02.002","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"56 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139829352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Profile and Outcomes of Carcinoma Penis patients receiving systemic therapy at an Indian tertiary care centre: A retrospective observational study","authors":"V. Noronha, Venkatesh Kapu, Amit Joshi, N. Menon, Ajay Singh, G. Prakash, S. Menon, N. Sable, V. Murthy, M. Pal, Amandeepsingh Arora, Sravan Kumar, S. Banavali, K. Prabhash","doi":"10.1016/j.clgc.2024.02.004","DOIUrl":"https://doi.org/10.1016/j.clgc.2024.02.004","url":null,"abstract":"","PeriodicalId":93941,"journal":{"name":"Clinical genitourinary cancer","volume":"1353 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139830965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}